---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-052471"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:23:23.325574+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio enters equity line with Keystone Capital for up to 2.05M shares

## Summary
- Company may sell up to 2,051,428 shares at market price, subject to 19.99% cap unless at-market.
- Initial commitment shares: 10,181 delivered at signing; additional shares on days 90 and 180.
- Proceeds will be used for working capital and general corporate purposes.
- Investor Keystone Capital cannot engage in short sales or hedging during agreement term.
- Fixed purchase limit: lower of 25,000 shares or $250,000; VWAP aggregate cap $10M.

## SEC filing metadata
- accession: 0001104659-24-052471
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924052471/0001104659-24-052471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924052471/tm2412796d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-052471
- JSON: https://secwatch.observer/filing/0001104659-24-052471.json
- Plain text: https://secwatch.observer/filing/0001104659-24-052471.txt

## Key facts
- Material Agreements
  Annovis Bio, Inc. entered into Common Stock Purchase Agreement with the Equity Line investor (the "ELOC Purchaser") valued at up to 2,051,428 shares (effective 2024-04-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Equity Line investor (the "ELOC Purchaser")
  - Value: up to 2,051,428 shares
  - Effective: 2024-04-25
  source text: On April 25, 2024, Annovis Bio, Inc., a Delaware corporation (the “Company”), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with the Equity Line investor (the “ELOC Purchaser”), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to 2,051,428 shares of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) (but subject to the limitations described below).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924052471/0001104659-24-052471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.